Drug discovery is being reshaped by generative AI, structure prediction, and a renewed appetite for previously undruggable targets.
Clinical pharmacology is moving away from MTD-driven oncology dose selection toward the FDA Project Optimus paradigm of optimized, tolerable dosing in registrational trials.
Pharmacogenomics is finally entering routine practice, driven by CPIC guidelines, payer coverage expansion, and pre-emptive panel testing in major US health systems.
Lipid nanoparticles transformed RNA medicine during the pandemic and now anchor an expanding pipeline of mRNA, siRNA, and CRISPR therapeutics including Casgevy, the first approved CRISPR-Cas9 product.
The FDA Modernization Act 2.0 has formally opened the door to non-animal alternatives, accelerating adoption of organ-on-chip, microphysiological systems, and AI-based in silico tox prediction in IND-enabling packages.
The regulatory environment in 2027 is defined by accelerated approval reform under FDORA, the rolling implementation of the Inflation Reduction Act's Medicare drug price negotiation, and ongoing harmonization through ICH.
Pharmacovigilance is being transformed by claims and EHR-based real-world evidence, NLP-driven signal detection on social media and call-center transcripts, and the FDA Sentinel system's expanding role in active surveillance.
Biologics now account for the majority of new molecular entity revenue, led by an exploding ADC pipeline (trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan) and a new generation of T-cell engagers including teclistamab, talquetamab, and tarlatamab.
Pharmaceutical manufacturing is under unprecedented scrutiny following nitrosamine recalls, the GLP-1 shortage and compounding controversy, and the geopolitical re-shoring push under the CHIPS-and-Science-era industrial policy.
mRNA platforms have moved well beyond COVID into cancer, rare disease and in vivo cell therapy.
Antibody engineering drives much of biopharma innovation with bispecifics, ADCs and Fc-engineered platforms expanding rapidly.
ASOs, siRNAs and aptamers are reshaping rare and common disease therapy with multiple FDA approvals.
AlphaFold-3 and generative chemistry have moved AI from hype to working pipelines with multiple AI-designed candidates in clinical trials.
RWE shapes regulatory and reimbursement decisions with growing FDA acceptance.
Master protocols and adaptive designs accelerate development with multiple successful programmes.
Quality manufacturing underpins the industry with regulatory modernisation and continuous manufacturing transformation.
Generic and biosimilar competition shapes access with the post-IRA Medicare-negotiation environment changing economics.
Drug pricing and access dominate policy debate with multiple post-IRA implementation milestones.
Antimicrobial development addresses rising resistance with the post-CARB-X funding landscape requiring new incentive models.
Antiviral development extends from COVID antivirals to broad pathogens with multiple recent approvals.
Anticancer drug development is the most active therapeutic area with multiple FDA approvals annually.
CNS drug development faces unique challenges yet has produced multiple recent breakthroughs.
Endocrine therapeutics span obesity, diabetes, thyroid and bone health with the GLP-1 era expanding indications.
Pediatric drug development requires age-specific evidence with growing regulatory mandates.
Geriatric pharmacology addresses ageing-specific PK/PD with the growing elderly polypharmacy challenge.
Herbal and natural products are a growing category with both clinical interest and regulatory challenges.
Drug repurposing accelerates therapeutic development with multiple high-profile successes.
Orphan drug development has expanded with regulatory incentives across major jurisdictions.
Fixed-dose combinations and rational combinations improve outcomes across multiple therapeutic areas.
DDIs remain a major safety concern with post-IRA polypharmacy increasing complexity.
Pharmacoeconomic analysis informs reimbursement decisions with growing US uptake post-IRA.
Compounding pharmacy is under increased regulatory focus after high-profile incidents and the GLP-1 era.
Hospital pharmacy practice integrates clinical, operational and regulatory roles with workforce challenges.
PROTACs and molecular glues are a new therapeutic modality with multiple clinical-trial entries.
Pharmacovigilance is being modernised with AI, real-world data and patient-reported outcomes.